Trastuzumab-based combinations in metastatic breast cancer: How to make a choice

Clinical Breast Cancer

Volumn 4, Issue 1, 2003, Pages 28-38

  Jahanzeb, Mohammad ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Combination chemotherapy; Docetaxel; Paclitaxel; Platinum based chemotherapy; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; METHOTREXATE; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT EPIDERMAL GROWTH FACTOR; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BACKACHE; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CYTOPENIA; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE OVEREXPRESSION; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; NEUROTOXICITY; ONCOGENE NEU; ONYCHOLYSIS; PERIPHERAL NEUROPATHY; REVIEW; RISK BENEFIT ANALYSIS; STOMATITIS;

EID: 0038783098     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.009     Document Type: Review

References (62)

1. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-2648.
2. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719-726.
3. Mass R, Sanders C, Charlene K, et al. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the herceptin pivotal trials. Proc Am Soc Clin Oncol 2000; 19: (Abstract #291)
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
5. Osoba D, Slamon DJ, Burchmore M, et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20:3106-3113.
6. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95:1592-1600.
7. Konecny G, Pegram MD, Beryt M, et al. Therapeutic advantage of chemotherapy drugs in combination with Herceptin® against human breast cancer cells with HER-2/neu overexpression. Breast Cancer Res Treat 1999; 57:114 (Abstract #467).
8. Pegram, M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18:2241-2251.
9. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y. Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5′-dFUrd in human breast cancer models. Cancer Chemother Pharmacol 2002; 49:211-216.
10. Thomssen CH, Eidtmann H, Untch M, et al. Cardiac safety of epirubicin/cyclophosphamide (EC) alone and in combination with Herceptin in women with metastatic breast cancer (MBC). Breast Cancer Res Treat 2002; 76:S111 (Abstract #430).
11. Theodoulou M, Campos S, Welles L, et al. Preliminary cardiac safety and efficacy data from a phase I/II trial of TLC D-99 (D-99) and trastuzumab (T) in patients (PTS) with locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:46a (Abstract #180).
12. Eidtmann H, Thomssen C, Untch M, et al. Herceptin in combination with epirubicin plus cyclophosphamide: cardiac safety and efficacy in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:60a (Abstract #236).
13. Buzdar AU, Marcus C, Smith TL, et al. Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 1985; 55:2761-2765.
14. Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3:818-826.
15. Taxotere® (docetaxel) for Injection Concentrate [package insert]. Bridgewater, NJ: Aventis; 2002.
16. Taxol® (paclitaxel) injection [package insert]. Princeton, NJ: MeadJohnson Oncology Products; 2002.
17. Herceptin® Trastuzumab anti-HER2 monoclonal antibody [package insert]. South San Francisco, Calif. Genentech; 2002.
18. Robert N, Leyland-Jones B, Asmar L, et al. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76:S37 (Abstract #35).
19. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001; 19:2587-2595.
20. Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12:1545-1551.
21. Slamon D, Leyland-Jones B, Shak S, et al. Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17:98a (Abstract #377).
22. Krasna L, Janku F, Petruzelka L, et al. Herceptin (H) and Taxol (T) in the treatment of women with HER-2/Neu overexpressing metastatic breast cancer (MBC): prospective study. Proc Am Soc Clin Oncol 2001; 20:64b (Abstract #2006).
23. Chollet P, Moreau L, Mouret-Reynier F, et al. Addition of herceptin to Taxol for HER-2 over-expressing advanced breast cancer (ABC). Best results in skin metastasis. Proc Am Soc Clin Oncol 2001; 20:68b (Abstract #2020).
24. Seidman A, Fornier M, Esteva F, et al. Final report: weekly (W) herceptin (H) and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy by HER2 immunophenotype (IHC) and gene amplification [fluorescent in-situ hybridization (FISH)]. Proc Am Soc Clin Oncol 2000; 20:83a (Abstract #319).
25. Scholz U, Luck HJ, Schippert C, et al. Trastuzumab (Herceptin) combined with weekly paclitaxel in the treatment of metastatic breast cancer: a phase II study. Breast Cancer Res Treat 2000; 64:122 (Abstract #527).
26. Yeung KY, Gupta R, Haidak D, et al. Weekly (W) Herceptin® (H, trastuzumab) and one hour Taxol (T, paclitaxel) infusion (WHT) regimen for human epidermal growth factor receptor-2 (HER2) overexpressed (+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2000; 19:142a (Abstract #559).
27. Tsavdaridis D, Timotheadou. E, Christodoulou C, et al. Weekly administration of paclitaxel, as first line chemotherapy, and Herceptin (trastuzumab) in advanced breast cancer (ABC). Ann Oncol 2000; 11:32 (Abstract #131P).
28. Mrsic M, Bogdanic V, Labar B, et al. Trastuzumab plus paclitaxel in the treatment of advanced breast cancer: single-centre experience. Ann Oncol 2000; 11 (suppl 4):32 (Abstract #132P).
29. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of Taxol. J Clin Oncol 1991; 9:1704-1712.
30. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:1800-1808.
31. Uber KA, Nicholson BP, Thor AD, et al. A phase II trial of weekly docetaxel (D) and Herceptin (H) as first- or second-line treatment in HER2 over-expressing metastatic breast cancer. Proc Am Soc Clin Oncol 2001; 20:50b (Abstract #1949).
32. Montemurro F, Choa G, Faggiulo R, et al. Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer. A pilot phase II study. Proc Am Soc Clin Oncol 2002; 21:49b (Abstract #2009).
33. Raab G, Brugger W, Harbeck N, et al. Multicenter randomized phase II study of docetaxel (Doc) given q3w vs q1w plus trastuzumab (Tra) as first line therapy for HER2 overexpressing adjuvant anthracycline pretreated metastatic breast cancer). Breast Cancer Res Treat 2002; 76:114 (Abstract #443).
34. Meden H, Beneke A, Hesse T, et al. Weekly intravenous recombinant humanized anti-Her2 monoclonal antibody (trastuzumab) plus docetaxel in patients with metastatic breast cancer (MBC): a pilot study. Proc Am Soc Clin Oncol 2001; 20:60b (Abstract #1987).
35. Malik U, Sparano J, Manalo J, et al. Phase II trial of weekly docetaxel (taxotere) alone or in combination with trastuzumab (herceptin) inpatients with metastatic breast cancer. Proc Am Soc Clin Oncol 2000; 19:148a (Abstract #586).
36. Sparano JA, Malik U, Manalo J, et al. Phase II trial of weekly docetaxel (Taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer. Breast Cancer Res Treat 2000; 64:80 (Abstract #317).
37. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16:2659-2671.
38. Pienkowski T, Fumoleau P, Eiermann W, et al. Taxotere, cisplatin and Herceptin (TCH) in first-line HER2 positive metastatic breast cancer (MBC) patients, a phase II pilot study by the Breast Cancer International Research Group (BCIRG 101). Proc Am Soc Clin Oncol 2001; 20:70b (Abstract #2030).
39. Heinemann V, Stemmler J, Wohlrab A, et al. Gemcitabine and cisplatin +/- trastuzumab (Herceptin) in intensively pretreated metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; 21:61b (Abstract #2056).
40. Slamon DJ, Patel R, Nortlifelt R, et al. Phase II pilot study of Herceptin combined with Taxotere and carboplatin (TCH) in metastatic breast cancer (MBC) patients overexpressing the HER2-Neu proto-oncogene a pilot study of the UCLA network. Proc Am Soc Clin Oncol 2001; 20:49a (Abstract #193).
41. Yardley DA, Greco FA, Hainsworth JD, et al. Final results of the Minnie Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab in metastatic breast cancer. Breast Cancer Res Treat 2002;76:S113 (Abstract #439).
42. Nabholtz JM, Crown J, Yonemoto L, et al. Results of two open-label multicentre pilot phase II trials with Herceptin® in combination with docetaxel and platinum salts (Cis- or carboplatin) (TCH) as therapy for advanced breast cancer in women overexpressing HER2. Breast Cancer Res Treat 2000;64:82 (Abstract #327).
43. Crown J. TCH: a novel taxane-based combination [Peer View Press Web Site]. Available at: www.peerviewpress.com/peerview.nsf/release/072002i.html: Accessed January 8, 2003.
44. Domenech GH, Vogel CL. A review of vinorelbine in the treatment of breast cancer. Clin Breast Cancer 2001; 2:113-128.
45. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001; 19:2722-2730.
46. Jahanzeb M, Mortimer JE, Yunus F, et al. Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2+ metastatic breast cancer. Oncologist 2002; 7:410-417.
47. Bernardo G, Palumbo R, Bernardo A, et al. Weekly trastuzumab (Herceptin) and vinorelbine (Navelbine) in chemonaive patients with HER2-overexpressing metastatic breast cancer: a phase II trial. Ann Oncol 2002; 13(suppl. 5):51 (Abstract #181P).
48. Bunnell CA, Burnstein HJ, Marcom PK, et al. Multicenter phase II study of trastuzumab (T) and vinorelbine (V) as first-line therapy for HER2 overexpressing metastatic breast cancer. Ann Oncol 2002; 13 (suppl 5):50 (Abstract #180P).
49. Chan A, Untch M, Petruzelka L, et al. Multinational phase II study of Navelbine (N) and herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC). Breast Cancer Res Treat 2002;76:S112 (Abstract #434).
50. Filipovich E, Mayordomo JI, Isla D, et al. Chemotherapy with trastuzumab plus vinorelbine in patients with erb-B2 overexpressed tumor is active in metastatic breast cancer. Breast Cancer Res Treat 2002;76:S112 (Abstract #436).
51. O'Shaughnessy JA, Vukelja S, Marsland T, et al. Gemcitabine and trastuzumab for HER-2 positive metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res Treat 2001;64:302 (Abstract #523).
52. Bangemann N, Kuhle A, Ebert A, et al. Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC). Ann Oncol 2000; 11(suppl 4):143 (Abstract #653P).
53. Biganzoli L, Martin M, Twelves C. Moving forward with capecitabine: a glimpse of the future. Oncologist 2002; 7(suppl 6):29-35.
54. Qu G, Perez EA. Gemcitabine and targeted therapy in metastatic breast cancer. Semin Oncol 2002; 29:44-52.
55. Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy-a survey of 427 patients. Med Sci Monit 2002; 8:151-157.
56. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
57. Seidman AD, O'Shaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7(suppl 6):20-28.
58. Miller KD, Sisk J, Gize G, et al. Phase II study of gemcitabine, paclitaxel and trastuzumab in metastatic breast cancer; a Hoosier Oncology Group trial. Breast Cancer Res Treat 2002;76:S113 (Abstract #437).
59. Bighin C, Nicoletto O, Monfardini S, et al. A phase II study of HET regimen (trastuzumab, epirubicin and taxotere) as a first line treatment in metastatic breast cancer. Proc Am Soc Clin Oncol 2002; 21:40b (Abstract #1973).
60. Venturini M, Del Mastro L, Durando A, et al. TEX (Taxotere, epirubicin and Xeloda) regimen as first line chemotherapy in advanced breast cancer: a multicenter phase II study. Proc Am Soc Clin Oncol 2001; 20:48b (Abstract #1938).
61. Trigo J, Climent MA, Gil M, et al. Cardiac safety and activity of phase I study of 3-weekly Myocet in combination with weekly herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC). Proc Am Soc Clin Oncol 2002; 21:61a (Abstract #242).
62. Kaufman PA, Schwartz G, Dragnev K, et al. Phase I trial of Herceptin (H) and Navelbine (Nvb) for patients with HER2-/neu (+) advanced breast cancer. Breast Cancer Res Treat 2002; 76:S111 (Abstract #431).